CRISPR Therapeutics takes a swing at ALS gene editing in discovery deal with AAV upstart Capsida
When small biotech Capsida launched just a few months ago, it hit the scene with backing from drug giant AbbVie to chase AAV-delivered drugs for CNS. Now, the team has earned the support of one of the biggest names in gene editing — and it’s taking on a big challenge right away.
CRISPR Therapeutics has signed a deal with Capsida Biotherapeutics, a gene therapy player specializing in AAV engineering, to carve out a delivery mechanism for the company’s gene editing tech in ALS and rare neurodegenerative disorder Friedreich’s ataxia, the companies said Tuesday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.